Rare condition

Autosomal recessive infantile hypercalcemia

0

studies recruiting now

as of 7 Sept 2026

0

studies registered in total

as of 7 Sept 2026

0

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No registered studies found for Autosomal recessive infantile hypercalcemia.

ClinicalTrials.gov has no study listed under this name as of 7 Sept 2026. That can change, and there are other routes worth knowing about.

Keep watching

Get an email when a new Autosomal recessive infantile hypercalcemia study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Autosomal recessive infantile hypercalcemia

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (CYP24A1, SLC34A1).

Treatments being studied

16 approved treatments and 1 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Denosumab (Jubbonti)Approved: Plicamycin (Mithracin)Approved: Clodronic AcidApproved: Dexamethasone Sodium Phosphate (Ak-dex)Approved: Zoledronic Acid (Aclasta)Approved: Gallium Nitrate (Ganite)Approved: Prednisolone (Cortalone)Approved: Calcitonin Salmon (Calcimar)Approved: Pamidronic AcidApproved: Prednisone (Cortan)Approved: Cinacalcet Hydrochloride (Cinacalcet accordpharma)Approved: Cortisone Acetate (Cortate)Approved: Ibandronic AcidApproved: Ibandronate Sodium (Bondenza (previously ibandronic acid roche))Approved: Dexamethasone (Aeroseb-dex)Approved: Zoledronic Acid Anhydrous
Phase 1Rifampin (Eremfat)

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).